89892-96-6Relevant academic research and scientific papers
METHOD FOR PURIFYING 4-HALO CYCLOHEXANE-1-CARBOXYLIC ACID, AND METHODS FOR PRODUCING PRODUCTS CONTAINING 4- HALO CYCLOHEXANE-1-CARBOXYLIC ACID
-
Paragraph 0029-0036, (2020/03/31)
To provide a method for purifying a 4-halo cyclohexane-1-carboxylic acid which can be highly purified without performing column purification, and a method for producing a product containing the 4-halo cyclohexane-1-carboxylic acid.SOLUTION: There is provided a method for purifying a 4-halo cyclohexane-1-carboxylic acid comprising a crystallization step of subjecting a mixture including a 4-halo cyclohexane-1-carboxylic acid and a 3-halo cyclohexane-1-carboxylic acid to a crystallization operation in a mixed solvent of water and a water-soluble organic solvent or a hydrocarbon solvent to increase a content of the 4-halo cyclohexane-1-carboxylic acid.SELECTED DRAWING: None
A nitric oxide-dexamethasone and preparation method and use thereof
-
, (2017/01/17)
The invention relates to nitric oxide donor type hexadecadrol as well as a preparation method and application thereof. The nitric oxide donor type hexadecadrol as a compound is obtained by enabling nitrous acid ester to be connected with hexadecadrol through ethyl cyclohexanecarboxylate; the in-vitro antiinflammatory activity of the nitric oxide donor type hexadecadrol is better than that of the hexadecadrol; besides, the nitric oxide donor type hexadecadrol can restrain the growth of methicillin-resistant staphylococcus aureus (MRSA) in vitro, restrain the formation of MRSA biomembrane, and lead to the death of bacteria in the MRSA biomembrane. In addition, the compound can notably increase the survival rate of mice in MRSA sepsis lethal models, reduces the inflammation pathology damage of the mice in sub-sepsis models, decreases the constant value number of bacteria, and has notable advantages in the respect of preventing and treating MRSA sepsis.
